key: cord-0798576-qdkx10nh authors: Huang, Jiaofeng; Cheng, Aiguo; Lin, Su; Zhu, Yueyong; Chen, Gongping title: Individualized prediction nomograms for disease progression in mild COVID‐19 date: 2020-05-17 journal: J Med Virol DOI: 10.1002/jmv.25969 sha: 3526eddf35c4de58a009b79ec3da1568c94c56ee doc_id: 798576 cord_uid: qdkx10nh The coronavirus disease 2019 (COVID‐19) has evolved into a pandemic rapidly. The majority of COVID‐19 patients are with mild syndromes. This study aimed to develop models for predicting disease progression in mild cases. The risk factors for the requirement of oxygen support in mild COVID‐19 were explored using multivariate logistic regression. Nomogram as visualization of the models was developed using R software. A total of 344 patients with mild COVID‐19 were included in the final analysis, 45 of whom progressed and needed high‐flow oxygen therapy or mechanical ventilation after admission. There were 188 (54.7%) males, and the average age of the cohort was 52.9 ± 16.8 years. When the laboratory data were not included in multivariate analysis, diabetes, coronary heart disease, T ≥ 38.5℃ and sputum were independent risk factors of progressive COVID‐19 (Model 1). When the blood routine test was included the CHD, T ≥ 38.5℃ and neutrophil‐to‐lymphocyte ratio were found to be independent predictors (Model 2). The area under the receiver operator characteristic curve of model 2 was larger than model 1 (0.872 vs 0.849, P = .023). The negative predictive value of both models was greater than 96%, indicating they could serve as simple tools for ruling out the possibility of disease progression. In conclusion, two models comprised common symptoms (fever and sputum), underlying diseases (diabetes and coronary heart disease) and blood routine test are developed for predicting the future requirement of oxygen support in mild COVID‐19 cases. world, mild cases are recommended to stay at home with symptomatic treatment until a deterioration in many countries. 7 Apart from the physical discomfort, the panic in the possibility of disease progression is another serious problem. There is no simple tool for patients who are self-isolated to quickly access individual risk for disease progression. As all patients with COVID-19 have been hospitalized in China regardless of the severity of diseases, 8, 9 thus we have baseline data of mild COVID-19 and the follow-up data of disease progression. Herein we included patients with mild symptoms on admission to explore the risk factor for the requirement for aggressive treatment (defined as high-flow oxygen supply, invasive or noninvasive mechanical ventilation) and develop simple tools for patients and doctors to predict the outcomes of mild COVID-19. Data were extracted from electronic medical records. Onset time was defined as the time from the first relevant symptom of COVID-19 to the time of admission. Those who smoked more than 10 cigarettes/day in the past 30 days were considered current smoker. 11 Heavy drinking was defined as long-term habitual alcohol consumption, usually longer than 5 years, of more than 40 g/d in males and 20 g/d in females, or a history of binging on alcoholic beverages within the past 2 weeks with a converted alcohol intake > 80 g/d. 12 The comorbidity of interest that was recorded was hypertension, diabetes mellitus (DM), coronary heart disease (CHD), cerebrovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and cancer. All blood samples were obtained at admission and analyzed by standard methods in the laboratory. The routine hematological and biochemical tests included measurement of white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, fibrinogen, d-dimer, liver and kidney function tests. Neutrophil-to-lymphocyte ratio (NLR) value was measured by dividing the neutrophil count by the lymphocyte count. This definition of disease progression in this study was based on the practical need, which was, a self-isolated COVID-19 patient usually went to the hospital seeking for oxygen support because of dyspnea. According to whether they needed oxygen support (including highflow oxygen supply, invasive or noninvasive mechanical ventilation) or not, they were divided into the stable group and the progressive group. Continuous variables were expressed as means ± SD or medians with interquartile ranges (IQRs), according to whether the distribution was normal or skewed. The Student t test was used for the comparison of normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. Categorical variables were expressed as percentages and examined with the χ 2 test or Fisher's exact test as appropriate. The nomogram was developed based on a logistic regression model, which allowed us to obtain significant COVID-19 progress probability estimations. An area under the receiver operator characteristic curve (AUROC) was used as a measure of diagnostic accuracy. A P-value < .05 was considered statistically significant. Data management and analysis were performed using R software (R (2.6%), 9 (2.6%), and 9 (2.6%) patients, respectively. The most common symptoms on admission were fever (78.5%) and cough (73.3%), followed by increased phlegm/sputum production (45.3%) and dyspnea (11.3%). A total of 15 (4.4%) patients eventually died (Table 1 ). Table 1 presents a comparison between the stable group and the progressive group. Compared with stable patients, those with disease progression were older, more likely to be male, with more comorbidities, and had a longer time of symptoms (P < .05). The la- Table 3 ). The AUROC of model 2 was larger than model 1 (0.872 vs 0.849, P = .023). Two AUROC curves of the two models are presented in Figure 2 . The visualization of the two models was presented as nomograms ( Figure 3 ). At present, oxygen supports (including high-flow oxygen supply, invasive or noninvasive mechanical ventilation) are facing serious shortages, even in developed countries. 13, 14 Therefore, it is very important to identify patients who do not need special oxygen inhalation, because these patients can be treated in isolation at home. This study developed two models for predicting disease progression in mild COVID-19. Model 1 included only age, symptoms, and underlying diseases, which was more convenient for patients on self-isolation to use. Blood routine tests have been added in model 2, which was mainly developed for doctors to quickly assess the risk with simple laboratory examination and facilitated early decision making. The nomogram as the visualization of these models could serve as a simple tool for doctors and patients to calculate individual risk. Comorbidities have already been proved to be associated with the severity of COVID-19 by large amounts of literature. 5, 6, [15] [16] [17] [18] [19] [20] [21] In these two models, we found diabetes and CHD were the most powerful impact factors rather than any other comorbidity. As reported by the latest research, diabetic patients with COVID-19 had higher expression of inflammation-related markers such as C-reactive protein and interleukin-6, indicating they were prone to develop systemic inflammation and severe COVID-19. 18 Patients with heart disease are more vulnerable to the hypopnea and pulmonary infection in COVID-19, thus more likely to have deterioration in symptoms. 22, 23 With additional blood routine indexes (including WBC and NLR), Model 2 showed a higher diagnostic value than model 1. Note: Continuous variables were expressed as means ± SD or medians with interquartile ranges (IQRs). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CVD, cerebrovascular disease; DBP, diastolic pressure; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; HR, heart rate; ICU, intensive care unit; LDH, lactic dehydrogenase; NLR, Neutrophil-to-lymphocyte ratio; RR, respiratory rate; SBP, systolic pressure; WBC, white blood cell count. NLR is increasingly recognized as a systemic inflammation factor, and the test is available in almost all laboratories. 19, 24 The latest meta-analysis showed that NLR reflecting an enhanced inflammatory process may suggest a poor prognosis of COVID- 19. 25 In addition, many population-based studies have shown that an elevated level of NLR can be considered an independent risk factor for indicating the poor outcome of COVID. 19, 26, 27 There were several limitations to this study. This study was a single-center study with relatively small sample size. Moreover, due to the limited cases with disease progression, the internalexternal validation of these models was not able to be performed in this study. These two models had low PPV, which meant that the probability of screening positive patients was relatively low. However, the high NPV could make people of home quarantine at ease with stay at home treatment. In conclusion, we developed two simple nomogram models as tools for predicting disease progression in mild COVID-19. From SARS to COVID-19: a previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans-call for a One Health approach COVID-19) Outbreak Situation COVID-19 in post-transplantation patients-report of two cases Epidemiological trends of COVID-19 epidemic in Italy during Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Coronavirus disease 2019 (COVID-19): a guide for UK GPs Prediction for progression risk in patients with COVID-19 pneumonia: the CALL Score Prediction models for diagnosis and prognosis of COVID-19 infection: systematic review and critical appraisal Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance Comparing cigarette smoking knowledge and attitudes among smokers and non-smokers Guidelines for the diagnosis and management of alcoholic liver disease: update Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA Use of non-invasive ventilation for patients with COVID-19: a cause for concern? COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Clinical characteristics of coronavirus disease 2019 in China Diabetes is a risk factor for the progression and prognosis of COVID-19 Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review The impact of COPD and smoking history on the severity of Covid-19: a systemic review and metaanalysis An acute respiratory infection runs into the most common noncommunicable epidemic-COVID-19 and cardiovascular diseases Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study Neutrophil-lymphocyte ratio as predictor of mortality and morbidity in cardiovascular surgery: a systematic review Neutrophil-to-lymphocyte ratio and lymphocyteto-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients Individualized prediction nomograms for disease progression in mild COVID-19 All authors contributed to the manuscript for important intellectual content and approved the submission. JH and AC designed the study and drafted the manuscript. AC acquired and did the statistical analysis. SL and JH made a critical revision. Yueyong Zhu and Gongping Chen did the study supervision. Ethical approval for the study was obtained from the Ethics Com- , which is used to assign a corresponding value for risk of significant fibrosis. CHD, coronary heart disease; DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio